NCT04203524 (Pro-Can) is a NA clinical trial of Procalcitonin Levels in Sepsis, sponsored by King Hussein Cancer Center.

Who is sponsoring NCT04203524?

NCT04203524 is sponsored by King Hussein Cancer Center.

What drugs are being tested in NCT04203524?

Interventions in NCT04203524: Procalcitonin Levels, Control.

What condition does NCT04203524 study?

NCT04203524 studies Sepsis, Septic Shock, Neoplasm, Critical Illness.

Is NCT04203524 still recruiting?

NCT04203524 is currently terminated. Last updated 17 March 2025.

Last reviewed 2025-03-17 · How we verify

NCT04203524: Pro-Can

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Procalcitonin and Antimicrobial Utilization in Critically Ill Cancer Patients with Sepsis

Terminated NA Last updated 17 March 2025

What this trial tests

NA trial testing Procalcitonin Levels in Sepsis in 157 participants. Terminated before completion.

Timeline

21 August 2019

Primary endpoint
1 March 2023

1 March 2023

Quick facts

Lead sponsor	King Hussein Cancer Center
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	157
Start date	21 August 2019
Primary completion	1 March 2023
Estimated completion	1 March 2023
Sites	1 location across Jordan

Drugs / interventions tested

Procalcitonin Levels
Control

Conditions studied

Sepsis — all drugs for Sepsis →
Septic Shock — all drugs for Septic Shock →
Neoplasm — all drugs for Neoplasm →
Critical Illness — all drugs for Critical Illness →

Sponsor

King Hussein Cancer Center — full company profile →

Who can join

18 and older, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Studies have demonstrated that the use of a procalcitonin (PCT)-guided algorithm in combination with clinical judgment was associated with reduced antibiotic use without impacting mortality or treatment failure. Though several studies have evaluated the use of PCT in critically ill patients, there are limited studies that evaluated PCT in patients with cancer and many of the currently available studies have excluded immune-compromised patients. This is a randomized controlled trial that aims to evaluate the impact of a procalcitonin-guided algorithm on antibiotic utilization in critically ill cancer patients with sepsis. In addition, the study aims to evaluate the predictive value of PCT for predicting mortality and positive cultures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Procalcitonin-Guided Management and Duration of Antibiotic Therapy in Critically Ill Cancer Patients With Sepsis (Pro-Can Study): A Randomized Controlled Trial.
Nazer LH, Awad W, Thawabieh H, Abusara A, et al · · 2024 · cited 3× · PMID 39431961 · DOI 10.1097/cce.0000000000001173

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other King Hussein Cancer Center trials

Trials by the same sponsor.

NCT07271121 — Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL · Phase 2 · recruiting
NCT06689358 — Thoracic Paravertebral Block for Postoperative Pain Management After VATS · NA · completed
NCT04374903 — Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients · NA · withdrawn
NCT04920513 — Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for · completed
NCT04920656 — Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04203524 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by King Hussein Cancer Center
Last refreshed: 17 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04203524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing